


 CrossMark  
 click for updates

 Cite this: *RSC Adv.*, 2015, 5, 17041

DOI: 10.1039/c5ra90008e

[www.rsc.org/advances](http://www.rsc.org/advances)

## Correction: Biocompatible graphene oxide as a folate receptor-targeting drug delivery system for the controlled release of anti-cancer drugs

Xubo Zhao and Peng Liu\*

 Correction for 'Biocompatible graphene oxide as a folate receptor-targeting drug delivery system for the controlled release of anti-cancer drugs' by Xubo Zhao *et al.*, *RSC Adv.*, 2014, 4, 24232–24239.

The authors regret a mistake regarding the discussion of the cytotoxicity assay in the above article:

The description of the determination of the cytotoxicity was incorrect. The WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1,3-benzene disulfonate) assay was used for cell toxicity studies in KB cells, rather than the MTT assay in HepG2 cells. For the WST-1 assay, the cells were seeded into 96-well plates at densities of  $1 \times 10^5$  cells per well for 24 h, and washed. Then, CG-PEG-FA nanocarriers at different concentrations, drug-loaded CG-PEG-FA and CG-PEG nanocarriers, and DOX were added to the cells and incubated for 24 h. Thereafter, direct detection at 450 nm was processed for the WST-1 assay to determine the cell viability.

These corrections do not influence any descriptions or conclusions in the article.

The Royal Society of Chemistry apologises for these errors and any consequent inconvenience to authors and readers.

